Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

The Dendritic Cell System and its Role in Immunogenicity

1991 • 4,733 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1998 • 2,373 citations

Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells

2001 • 1,384 citations

The Central Role of CD4+ T Cells in the Antitumor Immune Response

1998 • 1,332 citations

Malignant Melanoma

1979 • 1,323 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

2001 • 828 citations

Prognostic factors in 1,521 melanoma patients with distant metastases.

1995 • 567 citations

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

2001 • 535 citations

Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors

1997 • 432 citations

Generation of Tumor Immunity by Bone Marrow-Derived Dendritic Cells Correlates with Dendritic Cell Maturation Stage

1999 • 430 citations

Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4⁺T lymphocytes

1999 • 383 citations

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generatedin vitro from CD34+ hematopoietic progenitor cells

2000 • 337 citations

Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity

2000 • 337 citations

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

1995 • 324 citations

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

1996 • 285 citations

Increasing Incidence of Cutaneous Melanoma in Queensland, Australia

1992 • 271 citations

Identification of T-Cell Epitopes

1993 • 232 citations

CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity

2000 • 222 citations

Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells

2000 • 202 citations

Alterations in T cell receptor and signal transduction molecules in melanoma patients.

1995 • 192 citations

Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100

2000 • 179 citations

Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma

2001 • 171 citations

Cytoplasmic Processing Is a Prerequisite for Presentation of an Endogenous Antigen by Major Histocompatibility Complex Class II Proteins

2000 • 151 citations

Immunotherapy of Metastatic Malignant Melanoma by a Vaccine Consisting of Autologous Interleukin 2-Transfected Cancer Cells: Outcome of a Phase I Study

1999 • 125 citations

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.

1997 • 124 citations

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

1998 • 112 citations

CD40 is a prognostic marker in primary cutaneous malignant melanoma.

1996 • 92 citations

Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology.

1998 • 80 citations

Antitumor vaccination: where we stand.

2000 • 76 citations

The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.

1997 • 70 citations

Skin Cancers Associated With Acquired Immunodeficiency Syndrome

1995 • 68 citations

Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?

2000 • 68 citations

IMMUNOCOMPETENCE, IMMUNODEFICIENCY AND PROGNOSIS IN CANCER*

1976 • 61 citations

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

2001 • 55 citations

Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors.

2001 • 55 citations

Assessment of delayed-type hypersensitivity in man: A comparison of the “Multitest” and conventional intradermal injection of six antigens

1985 • 53 citations

Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy

1999 • 53 citations

Adjuvant therapy of melanoma

1998 • 47 citations

Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.

2000 • 41 citations

Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.

1993 • 41 citations

Cell-based vaccination against melanoma – background, preliminary results, and perspective

1999 • 39 citations

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy

1975 • 35 citations

The Labyrinthine Ways of Cancer Immunotherapy–T Cell, Tumor Cell Encounter: “How Do I Lose Thee? Let Me Count the Ways”

1998 • 28 citations

Active specific immunization in the treatment of patients with melanoma.

1996 • 26 citations

Functional effects of a monoclonal antibody directed against a distinct epitope on 4F2 molecular complex in human peripheral blood mononuclear cell activation

1991 • 13 citations

Serial circulating immune complex values and development of metastatic disease in breast cancer and malignant melanoma patients

1986 • 7 citations

Peripheral lymphocyte count and suppopulations of T and B lymphocytes in benign and malignant diseases.

1977 • 6 citations

Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma

2001 • 5 citations

In vitro monocyte maturation in patients with malignant melanoma and colorectal cancer--clinical significance.

1986 • 2 citations